** Shares of Spyre Therapeutics SYRE.O fall 5.1% post-market to $17.96 as it seeks equity raise

** Waltham, Massachusetts-based biotech, focused on treating inflammatory bowel disease and other immune-mediated diseases, commences offering of stock and pre-funded warrants without disclosing targeted deal size

** Jefferies, TD Secs, Leerink and Stifel are joint bookrunners

** Co has ~60.4 mln shares outstanding for about $1.1 bln market cap

** SYRE shares on Mon finished down 1.2% at $18.92. Stock has risen about 13% over the past week, but is still down ~19% YTD

** 12 of 13 analysts rate SYRE "strong buy" or "buy", 1 rates "hold" and median PT is $56, per LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))